ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2009
Biology and treatment of primary central nervous system lymphoma.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).The Cochrane database of systematic reviews · 2012Pooled it
- Immunotherapy in central nervous system tumors.International journal of surgery (London, England) · 2025Review
- Primary neurolymphomatosis with MAG antibody: a case report.BMC neurology · 2024Article
- Recent advances and challenges in primary central nervous system lymphoma: a narrative review.Translational cancer research · 2023Review
- Development and validation of a nomogram to predict overall survival and cancer-specific survival in patients with primary intracranial malignant lymphoma: A Retrospective study based on the SEER database.Frontiers in oncology · 2022Article
- Case report: Ventricular primary central nervous system lymphoma with partial hypointensity on diffusion-weighted imaging.Frontiers in neurology · 2022Article
- Primary central nervous system lymphoma: advances in MRI and PET imaging.Annals of lymphoma · 2021Article
- Extreme intracranial pressure elevation > 90 mmHg in an awake patient with primary CNS lymphoma-case report.Acta neurochirurgica · 2020Article
- Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
- Clinical Features of Primary and Systemic Metastatic Intraocular Lymphomas in Spanish Patients.Journal of ophthalmology · 2019Article
- Complications of immunosuppressive/immunomodulatory therapy in neurological diseases.Current treatment options in neurology · 2012Article
- Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.CNS drugs · 2012Review
- Good news-bad news: the Yin and Yang of immune privilege in the eye.Frontiers in immunology · 2012Article
- Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.Cellular & molecular immunology · 2011Review
- Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.Journal of Korean medical science · 2011Article
- Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010Article
- Targeting CXCL13 During Neuroinflammation.Advances in neuroimmune biologyArticle
- Primary fourth ventricular B-cell lymphoma in an immunocompetent patient.Clinical neuropathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare variant of extranodal non-Hodgkin lymphoma that is restricted in distribution to the brain, leptomeninges, spinal cord, and intraocular compartments. Although PCNSL shares overlapping features with systemic lymphoma, recent studies also reveal a unique pattern of gene and protein expression in PCNSL. These findings have yielded new insights into the pathophysiology of the disease, as well as the identification of novel prognostic biomarkers. Immune system compromise, such as is seen in acquired immune deficiency syndrome (AIDS), is the best established known risk factor for PCNSL. Like other lesions of the brain, meninges, and eye, the presenting symptoms associated with PCNSL typically include focal neurological deficits related to the site of disease or more global consequences of increased intracranial pressure. Diagnosis of PCNSL typically includes gadolinium-enhanced MRI and pathologic tissue analysis, as well as additional studies aimed at excluding concurrent systemic disease. PCNSL typically has a worse overall prognosis than systemic lymphoma. High-dose chemotherapy, particularly with methotrexate-based regimens, is the backbone of therapy for most patients, and chemotherapy is associated with much lower rates of treatment-related morbidity and mortality than whole-brain irradiation. Autologous stem cell transplantation is an emerging treatment modality, particularly in younger patients with relapsed disease, but high rates of treatment-related mortality are observed in older patients. Immunotherapy, including treatment with intrathecal rituximab, is another area of active research that may have promise in refractory or relapsed disease. Treatment options for intraocular lymphoma parallel those for PCNSL elsewhere in the brain: systemic chemotherapy, radiation, and local delivery of cytotoxic and immunologically active agents such as anti-CD20 antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.